← All indications
Leukemia, Plasma Cell
A rare, aggressive variant of MULTIPLE MYELOMA characterized by the circulation of excessive PLASMA CELLS in the peripheral blood. It can be a primary manifestation of multiple myeloma or develop as a terminal complication during the disease.
Drugs by status
Phase 2 trials (42)
- allopurinol
- allogeneic natural killer cells
- urea
- busulfan
- carfilzomib
- lenalidomide
- doxorubicin
- elotuzumab
- filanesib
- gemcitabine
- tacrolimus
- l-glutamine
- ixazomib
- palifermin
- panobinostat
- carmustine
- allogeneic hematopoietic stem cells
- Isatuximab
- sirolimus
- sns01-t
- mycophenolate
- cyclophosphamide
- stem cells
- Anti-thymocyte Globulin (Rabbit)
- bortezomib
- autologous umbilical cord blood
- allogeneic bone marrow
- fludarabine
- daratumumab
- pyridoxine
- +12 more
Phase 1 trials (5)
Other trials (3)
Organizations
Organization Involved with Phase 2 Indications (28)
- Celgene
- Millennium Pharmaceuticals
- Novartis
- Array BioPharma
- Clinical Service, China
- Sevion Therapeutics
- Otsuka
- National Institutes of Health (NIH)
- National Cancer Institute (NCI)
- National Heart, Lung, and Blood Institute (NHLBI)
- Huazhong University of Science and Technology
- University of Washington
- Gruppo Italiano Malattie EMatologiche dell'Adulto
- Harbin Medical University
- IRCCS Centro di Riferimento Oncologico della Basilicata
- Johns Hopkins University
- University of Michigan
- University of South Florida
- Mayo Clinic
- Capital Medical University
- Peking University
- University of Minnesota
- City of Hope National Medical Center
- University of Texas at Houston
- Henan Medical University
- Second Military Medical University
- People's Liberation Army of China
- University of Picardie Jules Verne
Organization Involved with Phase 1 Indications (4)
Organization Involved with Other Experimental Indications (1)